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In vitro EVALUATION OF QUINIDINE SENSITIVITY IN BRAZILIAN Plasmodium falciparum ISOLATES:
COMPARATIVE ANALYSIS TO QUININE AND CHLOROQUINE
Carla M. S. MENEZES(1), Karin KIRCHGATTER(2), Sílvia Maria DI SANTI(2), Gilberto A. PAULA(3) & Elizabeth I. FERREIRA(1)
SUMMARY
Falciparum malaria represents a serious and an increasing world public health problem due to the acquired parasite’s resistance
to the most available drugs. In some endemic areas, quinidine, a diastereoisomer of the antimalarial quinine, has been employed for
replacing the latter. In order to evaluate the use of quinidine as an alternative to the increasing loss of quinine effectiveness in
Brazilian P. falciparum strains, as has been observed in the Amazon area, we have assayed quinidine, quinine and chloroquine. The
in vitro microtechnique was employed. All isolates showed to be highly resistant to chloroquine. Resistance to quinine was not noted
although high MIC (minimal inhibitory concentration) values have been observed. These data corroborate the decreasing sensitivity
to quinine in strains from Brazil. Quinidine showed IC50 from 0.053 to 4.577 mmol/L of blood while IC50 from 0.053 to 8.132 mmol/
L of blood was estimated for quinine. Moreover, clearance of the parasitemia was observed in concentrations lower than that used for
quinidine in antiarrhythmic therapy, confirming our previous data. The results were similar to African isolate.
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INTRODUCTION
Current malaria chemotherapy was considered to start in the middle
of the XVII century with the jesuit’s discovery of the folkloric use of
Cinchona bark as a febrifuge by South American indians. However,
Artemisia annua was already known by Chinese population since the
beginning of the Christian era13, although the pharmacological studies
have started in the 70’s .
After its introduction in Europe, Cinchona tree bark powder begun
to be extensively employed in the treatment of fevers. In 1820, two
alkaloids, quinine (Fig. 1) and cinchonine, were isolated but the
antimalarial effect was attributed only to quinine. The pure alkaloid
replaced the Cinchona bark and quinine became the only drug in the
therapy and prophylaxis of malaria38.
The unavailability of quinine during World Wars I and II led to the
advent of the synthetic drugs, from which chloroquine stood out.
Considered to be the ideal antimalarial, chloroquine showed to be less
toxic, more effective and better to be administered than quinine, therefore,
substituting it36.
Plasmodium falciparum strains resistance to chloroquine and to the
second-line therapy sulfadoxine-pyrimethamine since the 60’s led to the
re-introduction of quinine. This alkaloid has been specially used to treat
severe or complicated infections and chloroquine or mefloquine resistant
malaria. In the later ones, the combination therapy has been recommended
for maintaining the antimalarial effectiveness. For instance, tetracycline
has been used in combinations with quinine40. Quinine resistant strains
were identified in the early stages of the drug usage. Lately, a continuous
decreasing in parasite sensitivity has been noted along different endemic
areas8,24,27. This has increased the interest in using quinidine (Fig. 1), the
dextro-rotatory diastereoisomer of quinine, as an alternative therapy.
Quinidine had its antimalarial activity despised in function of quinine.
Recognized as a potent antiarrhythmic agent, quinidine has been mostly
employed in the cardiovascular therapy since the 20’s29. Nevertheless,
in vitro, in vivo and clinical studies have reported quinidine as an effectiveFig. 1 -  Quinine (a) and quinidine (b).
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or even superior to quinine as an antimalarial agent5,7,11,21,22,24,25,32,33,39.
For a long time, quinidine has been considered by the Centers for Disease
Control (CDC/Drug Service) in USA14,15 to be the drug of choice in the
treatment of complicated P. falciparum infection. Since the 80’s it has
shown to be useful for treating pregnant women with severe falciparum
malaria25, since abortifacient properties are alleged to quinine40. Moreover,
quinidine, available worldwide, has increasingly been the only useful
therapy for severe and complicated malaria since USA stopped the
manufacture of quinine25.
With the purpose of facing the challenge of quinine effectiveness
decrease in Brazilian P. falciparum strains1,2,8,9,16,26,34,41, we evaluated the
in vitro sensitivity of isolates from North Brazilian States to quinidine in
comparison to quinine and chloroquine. We were based on previous
studies when quinidine showed to exert antimalarial effect in
concentrations many times inferior than those used in the cardiovascular
therapy23.
MATERIAL AND METHODS
Drugs - The drugs used were quinidine bisulphate dihydrate (Asta
Médica Ltda), quinine sulphate (Central de Medicamentos, CEME) and
chloroquine diphosphate (Fundação para o Remédio Popular, Furp).
Isolates - Six isolates of P. falciparum were employed: Isolate 1 –
5,760 parasites/mm3; Isolate 2 – 65,280 parasites/mm3; Isolate 3 – 3,240
parasites/mm3 and Isolate 4 – 65,000 parasites/mm3. All these isolates
were assayed immediately after blood venum puncture. Isolates 1-3 were
obtained from patients infected in Brazilian Northern region and Isolate
4 from a patient infected in Angola. These people had not been submitted
to any antimalarial treatment for the previous 28 days10. Blood samples
were collected after formal consent from patients. Isolate 5 (SUCEN
S20-87) was obtained from a patient infected in Rondonia, Brazil, in
1987. Isolate 6 (Uganda Palo Alto) was used as a reference for
chloroquine sensitivity. Isolates 5 and 6 were assayed after
synchronization of 10% ring forms parasitemia.
Drug sensitivity assay - The biological assay was the in vitro
microtechnique28. 96 flat-bottom wells microplates contained quinidine
(at the same concentrations range than quinine), quinine and chloroquine
were titrated (Table 1). Each series included the usual antimalarial
therapeutic concentrations of quinine (1.14 mmol/L of blood) and
chloroquine (6.4 mmol/L of blood) as the medium of the twofold serial
dilutions. This procedure was adopted in analogy to the test for the
assessment of P. falciparum response to antimalarial drugs as stated by
WHO10.
The infected blood was diluted in culture medium to a 10%
haematocrit. The plates were incubated at 37 °C for 24-48 hours
(depending on schizont maturation) using the candle jar method37. The
number of schizonts with three or more nuclei was determined in 200
parasites in thick blood smear stained with Giemsa.
Schizonts growth at 1.6 mmol/L of blood for chloroquine and
51.2 mmol/L of blood for quinine were considered as threshold for
in vitro P. falciparum resistance24. The minimal inhibitory concentration
(MIC), defined as the lowest concentration that completely inhibited
schizont formation, was determined.
Statistical analysis – The parasitemia rate (number of parasites in
the different wells in relation to the control) in function of the
concentration was analyzed throughout the linear logistic model17 for
quinine and quinidine. According to this, coincident, parallel, concurrent
(1 intercept) and concurrent (2 intercepts) lines were fitted. The
comparisons were made with regard to the simplest model, coincident
lines. The goodness-of-fit statistic and the corresponding p-value were
computed to assess the adequacy of the model. A significance level of
10% was adopted. Then, the medium inhibitory concentration (IC50)
and the correspondent confidence interval (95%) were estimated for each
drug.
RESULTS
The in vitro sensitivity of P. falciparum isolates to quinidine and the
classical antimalarials quinine and chloroquine is shown in Table 1. Based
on MIC, all parasites showed to be resistant to chloroquine, except the
Isolate 6. Different susceptibility levels were observed to quinidine and
quinine. No resistance to quinine was detected.
The results of the statistical analysis are depicted in Tables 2 and 3
and in Figure 2. For Isolate 1 the best-selected model was the concurrent
lines (1 intercept). As the concentration increases, the parasitemia rate
decrease is higher for quinidine than for quinine, leading to a lower
quinidine IC50 (Table 3). For Isolate 2 parallel lines was the best-fitted
model, with the quinine parasitemia rate and consequent IC50 smaller
than those of quinidine. Even though none of the proposed models was
well fitted for Isolate 3, the concurrent lines model (2 intercepts) indicates
that for small and moderate concentrations quinine has a smaller
parasitemia rate while an opposite tendency appeares in larger
concentrations. Equal IC50 values were estimated. For Isolate 4, the
concurrent lines model (2 intercepts) was the selected model. From the
fitted lines, small concentrations of quinidine cause lower parasitemia
rates while an opposite behavior is observed in high concentrations.
Quinidine at 50% inhibition showed to be a worse antiplasmodial agent
than quinine. For Isolate 5, coincident lines was the selected model and
a common fitted line as well as estimated IC50 values were obtained. For
Isolate 6, concurrent lines (1 intercept) was the best-fitted model. In this
Table 1
In vitro sensitivity of P. falciparum isolates to chloroquine,
quinine and quinidine
Isolate Geographical MIC (mmol/L of blood)
Origin Chloroquine Quinine Quinidine
1 Para/Brazil ID 25.6 12.8
2 Para/Brazil ID 6.4 6.4
3 Amazonas/ 6.4 12.8 6.4
Brazil
4 Angola 6.4 6.4 25.6
5(SUCEN S 20-87) Rondonia/ 6.4 6.4 6.4
Brazil
6 (Palo Alto) Uganda 1.14 6.4 12.8
ID = impossible to determine (growth in the higher concentration of drug,
6.4 mmol/L of blood); MIC = minimal inhibitory concentration
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DISCUSSION
The loss in P. falciparum sensitivity to quinine in Brazil dated from
the beginning of the XX century. A continuous decrease has been reported
in special since the 80’s when quinine replaced chloroquine and
sulfadoxine-pyrimethamine in malaria resistant therapy. Then,
tetracycline began to be co-administered with quinine in order to
overcome the resistance problem and to reduce its inherent toxicity2,8,9.
Quinine is still considered a useful drug for treating non-complicated
falciparum malaria8. Nevertheless, a gradual increase in the time to clear
the parasitemia followed by an elevation in recurrence frequency were
observed in patients from the Eastern Amazon, where quinine was
employed during the quadriennial 1983-199426. Moreover, decrease in
quinine sensitivity was also evidenced in two recent reports performed
with Brazilian samples from Mato Grosso State, Amazon area16,41.
In our study, different susceptibility levels were observed among
the isolates in relation to quinine and quinidine. Resistance to quinine
was not detected since no schizont maturation was observed at
51.2 mmol/L of blood24. Nevertheless, decreasing in P. falciparum
susceptibility to quinine was confirmed, in particular, with Isolate 1 (the
highest IC50) and with Isolates 5 and 6, collected for a long time and
much more sensitive to quinine. These data corroborated recent
evaluations16,26,41, showing a unquestionable and worryingly loss of
quinine effectiveness in Brazilian strains. Interestingly, quinine was more
Table 3
Estimated median inhibitory concentration (IC50) and the confidence interval
concentration of quinine and quinidine
Drug Isolate Estimated IC50 95% Confidence
(mmol/L of blood) Interval
Quinine 1 8.132 5.330 ; 10.934
2 1.522 0.207 ; 2.836
3 0.053 0.000 ; 0.145
4 2.078 0.596 ; 3.560
5 2.203 1.002 ; 3.404
6 0.585 0.025 ; 1.145
Quinidine 1 4.577 1.690 ; 7.463
2 3.569 0.741 ; 6.396
3 0.053 0.000 ; 8.460
4 3.132 2.799 ; 3.466
5 2.203 1.002 ; 3.404
6 1.674 1.374 ; 1.974
Table 2
Results of the fitted linear logistic models for quinine and quinidine
Isolate Model Goodness-of-fit statistic Degrees of freedom p-value
1 Coincident lines 40.669 8 0.000
Parallel lines  9.537 7 0.216
Concurrent lines (1 intercept)  7.721 7 0.358
Concurrent lines (2 intercepts)  6.352 6 0.385
2 Coincident lines 40.673 8 0.000
Parallel lines  6.467 7 0.486
Concurrent lines (1 intercept) 21.963 7 0.002
Concurrent lines (2 intercepts)  4.053 6 0.669
3 Coincident lines 99.730 8 0.000
Parallel lines 32.179 7 0.000
Concurrent lines (1 intercept) 77.032 7 0.000
Concurrent lines (2 intercepts) 18.507 6 0.005
4 Coincident lines 42.640 8 0.000
Parallel lines 36.756 7 0.000
Concurrent lines (1 intercept) 17.098 7 0.017
Concurrent lines (2 intercepts)  9.588 6 0.143
5 Coincident lines  9.750 8 0.283
Parallel lines  9.741 7 0.203
Concurrent lines (1 intercept)  9.707 7 0.206
Concurrent lines (2 intercepts)  9.388 6 0.153
6 Coincident lines 32.364 8 0.000
Parallel lines  9.368 7 0.227
Concurrent lines (1 intercept)  7.124 7 0.416
Concurrent lines (2 intercepts)  5.734 6 0.454
case, the parasitemia rate of quinine was smaller than the quinidine and
the difference increases with the concentration. These results corroborate
the estimated IC50 values (Table 3).
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effective against the African isolate, Isolate 4. However, opposite data
have been obtained with isolates from Gabon24 and Niger35 and, also,
out of the African continent, in Thailand32. In addition, all isolates showed
to be highly resistant to chloroquine. MIC values were much higher
than the considered threshold concentration, 1.6 mmol/L of blood24.
We consider that as observed in former studies 5,7,11,21,22,24,25,32,33,39,
quinidine shows a promising activity against Brazilian P. falciparum
strains. Quinidine inhibitory effect was observed in concentrations lower
(estimated IC50 ranged from 0.053 to 4.577 mmol/L of blood that
corresponds to 0.0172 to 1.485 mg/mL) than those employed in
antiarrhythmic therapy, 2-6 mg/mL4. These results are in accordance to
our previous assay carried out with two North Brazilian P. falciparum
isolates23. Although further in vitro, in vivo, and clinical studies should
be conducted, the preliminary results here reported are indicative of the
possibility of using quinidine in uncomplicated but, especially, in
complicated and severe forms of falciparum malaria. This finding
assumes greater importance with the increasing loss of quinine efficacy
against Brazilian strains. Nevertheless, precautions have been
recommended concerning to the intravenous dispensing of quinidine
due to its inherent cardiotoxicity6,25,40. In addition, the exchange
transfusion after quinidine administration has been recommended for
rapidly reducing the parasitemia, lowering the mortality by severe
falciparum malaria20.
Notwithstanding, quinidine may also be used in combination with
other antimalarial agents as well as with its stereoisomers. Cinchona
alkaloid combinations have been successfully used for treating falciparum
malaria in endemic areas3,12,18,19,30,31. Quinidine, quinine and cinchonine
(QuinimaxÒ) or even quinidine, quinine, cinchonine and chinchonidine
have been employed by different administration routes for treating
uncomplicated as well as complicated falciparum malaria. These
combination regimens allow to reduce the individual doses of the
alkaloids, decreasing their inherent toxicities.
RESUMO
Avaliação da sensibilidade in vitro à quinidina em isolados
brasileiros de Plasmodium falciparum: análise comparativa à
quinina e à cloroquina
Malária falciparum representa grave e crescente problema de saúde
pública mundial, dada a resistência do parasito à maioria dos fármacos
disponíveis. Em algumas áreas endêmicas, a quinidina, diastereoisômero
do antimalárico quinina, vem sendo empregada em substituição a este
último. Com o objetivo de avaliar o emprego da quinidina como
alternativa à perda crescente de sensibilidade de cepas brasileiras de P.
falciparum à quinina, como o observado na região Amazônica, realizamos
ensaio comparativo entre quinidina, quinina e cloroquina. A técnica in
vitro do microteste de sensibilidade foi utilizada. Todos os isolados
mostraram-se altamente resistentes à cloroquina. Resistência à quinina
não foi observada, embora altos valores de CMI (concentração mínima
inibitória) tenham sido encontrados. Estes resultados corroboram o
decréscimo de suscetibilidade de cepas brasileiras à quinina. Observou-
se variação de IC50 de 0,053 a 4,577 mmol/L de sangue para a quinidina,
enquanto para a quinina estimou-se IC50 de 0,053 a 8,132 mmol/L de
sangue. Ademais, observou-se clareamento da parasitemia em
concentrações inferiores à da quinidina quando empregada como fármaco
antiarrítmico, confirmando estudo anterior por nós realizado. Resultados
semelhantes foram encontrados em isolado oriundo da África.
Fig. 2 - Observed parasitaemia rates for quinine (•) and quinidine (s) and fitted  linear logistic  models  for quinine (—) and quinidine (– –).
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